anti-CD19/anti-CD22 CAR T-cell therapy (MD Anderson Cancer Center/National Cancer Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD19/anti-CD22 CAR T-cell therapy (MD Anderson Cancer Center/National Cancer Institute)
Drug Alias Nameanti-CD19/anti-CD22 CAR T-cell therapy (MD Anderson/NCI)dual anti-CD19/anti-CD22 CAR T-cell therapy (MD Anderson Cancer Center/National Cancer Institute)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Non-Hodgkin +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A